Zika Active Project

Zika Active Project
Name	Zika Active Project
Abbreviation	Zika Active
Established	2016
Location	Brazil, Colombia, Puerto Rico
Focus	Zika virus surveillance, clinical trials, epidemiology
Affiliated institutions	Oswaldo Cruz Foundation; National Institutes of Health; University of California, Berkeley; Universidade de São Paulo

Zika Active Project The Zika Active Project was a multi‑site surveillance and research initiative launched in response to the 2015–2016 Zika virus epidemic in the Americas. The project integrated clinical, epidemiological, and entomological approaches to study transmission dynamics, congenital outcomes, and vaccine and diagnostic development. It operated through partnerships among public health agencies, academic institutions, and international research funders to inform policy and clinical practice during the outbreak.

Overview

The initiative combined household surveillance, cohort studies, and laboratory diagnostics to characterize Zika virus infection patterns across urban and rural settings. Teams conducted active case finding, longitudinal follow‑up, and serosurveys to quantify incidence, asymptomatic infection, and risk factors for adverse outcomes such as congenital Zika syndrome and microcephaly. The project informed clinical guidelines used by ministries of health and contributed data to multicenter consortia addressing arbovirus control, maternal‑child health, and vector management.

History and Development

Conceived amid the regional public health emergency declared by the Pan American Health Organization and the World Health Organization alert, the project emerged from collaborations among investigators at the Oswaldo Cruz Foundation, the National Institutes of Health, and university partners including University of California, Berkeley and Universidade de São Paulo. Early planning aligned with emergency research priorities set during the 2016 Summer Olympics planning and national response efforts in Brazil, Colombia, and Puerto Rico. The program built on prior surveillance platforms developed during outbreaks of Dengue fever and Chikungunya virus and incorporated lessons from vaccine trials such as those for Ebola virus disease and Influenza.

Methodology and Data Collection

Field teams used door‑to‑door enrollment, clinic‑based recruitment, and birth cohort follow‑up to assemble datasets linking maternal infection to infant outcomes. Laboratory methods included nucleic acid amplification testing similar to protocols refined by the Centers for Disease Control and Prevention and serological assays adapted from studies of West Nile virus and Yellow fever vaccine. Entomological surveillance used ovitrap arrays and insecticide resistance testing informed by vector control studies conducted in Rio de Janeiro, Bogotá, and San Juan. Data management adhered to standards modeled after large consortia including the Global Health Network and genomic surveillance initiatives like the Global Initiative on Sharing All Influenza Data.

Key Findings and Impact

Analyses quantified the risk window during pregnancy associated with congenital outcomes and clarified rates of asymptomatic Zika infection in populations previously exposed to Dengue virus. The project contributed evidence linking prenatal infection to neurodevelopmental sequelae documented in cohorts from Recife, Manaus, and Cali. Findings informed guidance from the World Health Organization and national agencies regarding travel advisories, reproductive health counseling, and screening recommendations. Data were incorporated into vaccine candidate evaluations and diagnostic validation studies conducted by partners such as the Food and Drug Administration and academic vaccine centers.

Collaborations and Funding

The project was implemented through networks including academic institutions, public health laboratories, and non‑governmental organizations. Key collaborators included the Oswaldo Cruz Foundation, the National Institutes of Health, the London School of Hygiene & Tropical Medicine, and regional ministries of health. Funding came from international donors and research agencies modeled on grant mechanisms used by the Bill & Melinda Gates Foundation, the Wellcome Trust, and government research councils such as the Brazilian National Council for Scientific and Technological Development and the National Science Foundation.

Criticism and Limitations

Critiques addressed generalizability given heterogeneous transmission and differing baseline immunity to flaviviruses across sites, echoing concerns raised in comparative studies of seroprevalence during arboviral outbreaks. Diagnostic cross‑reactivity with antibodies to Dengue virus complicated serological interpretation, a methodological issue also encountered in studies of Yellow fever and West Nile virus. Logistical constraints—including supply chain challenges observed during the 2014–2016 Ebola epidemic and the need for sustained surveillance infrastructure—limited long‑term follow‑up. Ethical debates involving reproductive counseling and data sharing paralleled controversies seen in emergency research during the Zika virus epidemic and other public health crises.

Category:Zika virus Category:Infectious disease research projects Category:Epidemiology